Physician profile
Anna E Lasota
NPI 1407175573
$2,323.72
in general payments reported to CMS, 2019-2025
32 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $71.16 · 2021: $228 · 2022: $774 · 2023: $291 · 2024: $334 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $356.16 | 2021-2025 | |
| Novo Nordisk INC | $293.14 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $285.33 | 2021-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $144.74 | 2019-2022 | |
| Amgen INC. | $142.28 | 2022-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $131.65 | 2019-2023 | Mounjaro |
| Pfizer INC. | $125.86 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $96.80 | 2019-2025 | Breztri, Farxiga |
| Sanofi-Aventis U.S. LLC | $85.60 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $73.94 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.02 | 2019-2022 | |
| Hologic Sales and Service, LLC | $69.09 | 2025 | Thinprep 2000 Processor, Aptima, Third Wave |
| Ironshore Pharmaceuticals INC. | $66.75 | 2019 | |
| Abbott Laboratories | $66.48 | 2022-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $36.42 | 2024-2025 | Dexcom G6 Transmitter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $30.95 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $29.54 | 2022 | |
| Smith+Nephew, INC. | $18.53 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.39 | 2023 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $15.98 | 2023 | Austedo |
| Idorsia Pharmaceuticals US INC | $15.74 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $15.42 | 2022 | |
| Ardelyx, INC. | $15.34 | 2024 | Ibsrela |
| Ultragenyx Pharmaceutical INC. | $15.24 | 2020 | |
| Amarin Pharma, INC. | $14.97 | 2021 | |
| Insulet Corporation | $14.65 | 2025 | Omnipod |
| Eisai INC. | $14.34 | 2021 | |
| Boston Scientific Corporation | $13.42 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.36 | 2024 | Lifevest |
| Glaxosmithkline, LLC. | $12.19 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.38 | 2021 | |
| Tris Pharma INC | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Lasota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.